ClinicalTrials.gg

Program

LM-350

A development code. Also written as “LM-350 for injection”.

In Sino Biopharmaceutical's pipeline, CDH17 ADC. Its studies are mostly in Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jul 16, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 2since Jul 16, 2025Jul 16, 2025Jun 30, 2028phase 2 · NCT07112222
  • Named in Sino Biopharmaceutical’s own pipeline as LM-350, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2025First study: phase 2 study in NeoplasmsFirst studyNCT07112222 · 80 planned · Australia, China

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in NeoplasmsNCT07112222

TargetBeta

“CDH17 ADC”the company's pipeline, read by Claude · source

Other programs on CDH17

ProgramCompanyFurthest phaseStudies
Anti-CDH17 Antibody-drug Conjugate HS-20110Hansoh Pharmaceutical Groupphase 22
Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911ruleMabwell (Shanghai) Biosciencephase 22
AMT-676rulemultitude-therapeutics-incphase 22
Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324ruledualitybio-incphase 21
Anti-CDH17 Antibody-drug Conjugate YL217ruleMediLink Therapeutics (Suzhou)phase 11
Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rulearrivent-biopharma-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07112222Neoplasms · Australia, China2RecruitingJun 30, 202880

How it is read

Names in the registry

  • “LM-350 for injection”, 1 entry

Codes read as this program: LM350.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.